Question 1

Almost 99% of the sickle cell patients I see in clinical practice cannot afford curative treatment options. How can I best improve quality of life for these patients?

Dr. Arun Singh Danewa · Accepted Answer

Hydroxyurea should be on the medication chart of every single patient, alongside L-glutamine, the two proven disease-modifying drugs. Vaccination against Haemophilus influenzae, pneumococcus, and Neisseria meningitidis should be part of every patient's care given their functional asplenia. Transcranial Doppler is important for any patient with a stroke history, and chronic transfusion therapy should start if the Doppler reading crosses the cutoff. Educating patients about precipitating factors for pain crisis, changes in weather and infection among them, is equally valuable where curative treatment is not accessible.

Question 2

If disease-modifying drugs continue to improve, will that eventually eliminate the need for bone marrow transplant?

Dr. Arun Singh Danewa · Accepted Answer

No. These drugs do not hit the primary pathology, the sickling process itself. They can reduce pain symptoms and severity, but the silent chronic organ damage keeps progressing underneath. Only bone marrow transplant and gene therapy correct the underlying disease, so a patient who can access and afford curative therapy should pursue it; supportive therapy remains the best option only where curative treatment is out of reach.

Question 3

Over a lifetime, would supportive therapy end up costing more than a bone marrow transplant?

Dr. Arun Singh Danewa · Accepted Answer

Yes, cumulatively the costs converge. Patients in their mid-thirties frequently say they would accept any transplant risk just to be rid of the disease. Adding up a lifetime of hospitalizations and medications produces a total broadly similar to the cost of transplant, the real difference is timing: transplant requires the full sum upfront in a short window, while supportive care is paid in smaller, less visible installments over decades.

Question 4

How many times can one person be a bone marrow donor?

Dr. Arun Singh Danewa · Accepted Answer

Usually a maximum of two times in a lifetime, under blood bank regulations in most countries. The minimum gap between two donations should be six months, occasionally reduced to three months in a life-threatening situation, though six months to a year is recommended. Most Indian regulations do not permit bone marrow donation beyond two times.

Question 5

If two siblings both have sickle cell disease and one sibling is a full-match donor, can that one donor's harvest be used for both patients?

Dr. Arun Singh Danewa · Accepted Answer

Yes, this is done in practice. Since the minimum stem cell dose is 3 million cells per kilogram of the recipient's weight, a larger harvest can be divided into two doses for two patients. Where families want to proceed with one transplant first and the second once funds are arranged, half the dose is used immediately and the rest is cryopreserved for the second transplant later, sometimes with additional stimulating injections used to boost the donor's total yield.

Question 6

If a patient undergoes a successful bone marrow transplant, grows up, and has children of their own, is the sickle cell inheritance chain broken for the next generation?

Dr. Arun Singh Danewa · Accepted Answer

No. Transplant replaces the blood-forming stem cell system, not the gene itself; the reproductive organs still carry the SS gene. The post-transplant patient will transmit one sickle gene to their offspring, and if their partner is also a carrier, their child can still be born with sickle cell disease. Families need to be counseled that both the patient and their partner should be tested once the child is grown and ready to have children of their own.

Question 7

Is it safe to do a bone marrow transplant in a child between one and two years old, when they cannot yet express symptoms during the process, or is it better to wait until they can?

Dr. Arun Singh Danewa · Accepted Answer

Transplant is safe from one year of age; the literature supports one year as the minimum, and the child's inability to verbally express discomfort is not the limiting factor, since transplants are routinely done for leukemia in infants as young as six to eight months when it is a do-or-die situation. What matters is that the body can tolerate the immunosuppression and the physical toll of the transplant, and that organs are sufficiently mature. One year is workable, but the preferred window remains two to five years, where outcomes are excellent.

Question 8

What are the chances of a sickle cell carrier experiencing a crisis?

Dr. Arun Singh Danewa · Accepted Answer

Extreme environmental changes can occasionally trigger mild to moderate symptoms even in a carrier. High altitude without acclimatization, or cold temperatures causing vasoconstriction, can be enough to provoke symptoms from the 25 to 30% sickle hemoglobin a carrier naturally has, but these episodes are far less frequent and less severe than in a full sickle cell patient. Notably, this is the same threshold, 25 to 30% sickle hemoglobin, that explains why sickle cell transplant patients only need that much stable donor chimerism to stay symptom-free.

Question 9

Can you walk through chimerism percentages at each time point, and what happens if the target isn't met at day 30?

Dr. Arun Singh Danewa · Accepted Answer

At day 30 the target is 95%, full donor chimerism. If it is falling, for example from 95% down to 70%, immunosuppressant drugs like cyclosporine or tacrolimus are reduced first and chimerism is rechecked after two weeks; if it recovers, reduced dosing continues. If it keeps falling, donor lymphocyte infusion follows, and a second transplant becomes necessary only if it drops below 5%. For the long term, the real target is stability rather than a fixed number, chimerism often settles at 50% or even 25 to 30% after some years, and if it holds there, the patient stays free of sickle symptoms, since sickle cell needs only 12 to 25% stable chimerism compared to the 80 to 85% required in thalassemia.

Question 10

Can you explain the immunological basis of graft rejection after a haploidentical transplant?

Dr. Arun Singh Danewa · Accepted Answer

There are two mechanisms. Antibody-mediated rejection happens when repeated blood transfusions leave a patient with donor-specific antibodies; if these are high, the graft is rejected outright and neutrophil engraftment never occurs, which is why a negative DSA result is mandatory before a haploidentical transplant, with desensitization required first if it is positive. Cell-mediated rejection happens when conditioning chemotherapy fails to fully eliminate the patient's own bone marrow, leaving residual recipient cells that reject the donor's stem cells. Preventing graft failure means confirming a negative DSA and using a sufficiently intense conditioning regimen.

Question 11

How do you manage a sickle cell patient who is also HIV-positive, and can the transplant address the HIV as well?

Dr. Arun Singh Danewa · Accepted Answer

There is no contraindication to transplanting a sickle cell patient who is HIV-positive; the only requirement is that the donor test HIV-negative, a standard part of viral marker screening. Because HIV resides in CD4 lymphocytes, conditioning chemotherapy removes the patient's existing lymphocyte population, and the donor's new cells do not carry the virus, so there are case reports of patients being cured of HIV alongside their primary condition. This is not the established standard of care for HIV, but it has been documented.

Question 12

In case of graft rejection, when can a bone marrow transplant be attempted again?

Dr. Arun Singh Danewa · Accepted Answer

It depends on the patient's condition, but since sickle cell disease is not immediately life-threatening the way leukemia is, the advice is to wait six months to a year to let the body recover, relying on supportive care in the interim rather than rushing back in. The same donor can be used again if they are still a full match, since a donor can donate up to twice in a lifetime, though switching donor type for the second attempt, for example from haploidentical to a matched unrelated donor or vice versa, is sometimes considered.

Question 13

Is there a test that can be done while a mother is pregnant to know the sickle cell status of the baby before birth?

Dr. Arun Singh Danewa · Accepted Answer

Yes. Where both partners are known sickle cell carriers, amniocentesis at 10 to 12 weeks of pregnancy is the ideal method, telling the family whether the baby is AA, AS, or SS. Cordocentesis at 18 to 20 weeks is a second option but carries a higher complication rate, which is why amniocentesis earlier in pregnancy is preferred. What happens with that information depends on the country's laws on termination and the family's own wishes.

Question 14

On the age cutoff for transplant, one colleague argues that existing organ damage should matter more than age itself, so even a 35-year-old with preserved organ function would be attempted, while a 15-year-old with multi-organ damage would not. What is your view?

Dr. Arun Singh Danewa · Accepted Answer

That view is correct. Age becomes a factor only because of the organ damage that accumulates alongside it, so a patient with well-preserved organs despite their age should not be disqualified, and a full-match sibling donor with good organ function can support a transplant well into a patient's thirties. Haploidentical transplant in older patients is approached more cautiously, since complications run higher there specifically. Counseling has to be transparent regardless of age, walking families through expected complications and risks based on a comprehensive pre-transplant evaluation, since organ damage is sometimes more advanced than a patient realizes.

Question 15

After the one-year mark, with chimerism doing well, will further sickling episodes occur, and will organ damage from before the transplant reverse?

Dr. Arun Singh Danewa · Accepted Answer

If chimerism is at an adequate, stable level, no further sickling will occur; this is an all-or-none outcome once stable chimerism is achieved, not something that happens intermittently. However, damage that occurred before transplant, such as disability from a prior stroke, does not reverse; the transplant stops further damage rather than undoing what has already happened. After the one-year mark with good chimerism, the chance of graft failure is under 5%, and after two to three years it is close to zero, so cure in this context means no further sickling and no further organ damage, not an undoing of pre-existing injury.

Question 16

Why cryopreserve stem cells rather than simply asking the donor to donate again later?

Dr. Arun Singh Danewa · Accepted Answer

Collected stem cells only survive about 72 hours at refrigerator temperature, 2 to 8 degrees, before they die. Cryopreservation stores them at minus 80 to minus 90 degrees, where they remain viable for about a year, the same technique used for sperm banking or oocyte preservation. This means a single donation is sufficient if enough dose is collected upfront, and the donor does not need to return for a second transplant planned months later.

Question 17

Sharing an update: how has your son been doing since his transplant?

Dr. Arun Singh Danewa · Accepted Answer

I traveled to India with my son for his transplant. We had a full-match donor, and chimerism was 100% at day 30, 60, and 90. There were no issues until we traveled back home, when he developed graft versus host disease in his eyes and skin. On review this year he was treated and chimerism was still 100% on recheck. He has now started his vaccinations after the one-year mark, we have dropped most of his medications, and he is back in school and doing well.

Sickle Cell Disease and Bone Marrow Transplant

Questions Doctors Asked Dr. Arun Singh Danewa